SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoins sharp rally is driving attention, with traders pointing to the Grayscale ETF filing and renewed interest in its proof-of-human identity use case amid growing AI-agent activity; some also cite Eightcos large WLD holdings as a source of institutional interest. Optimism about further gains and a potential short squeeze is tempered by skepticism over the tokens volatility and the fact that ETF approval remains uncertain.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbines volatile pullback and range-bound trading are driving discussion, with traders debating whether low-volume selling and options activity are weighing on shares or creating a buying opportunity ahead of earnings. Bullish investors point to improving growth and cash flow, while others remain concerned about dilution and the stocks weakness.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is drawing attention amid a high-volume rally and anticipation of founder Patrick Soon-Shiongs scheduled fireside chat, where investors are looking for trial updates. Traders also connect the broader NIH cancer-vaccine push to the companys investigational vaccine work; hopes for a partnership or short squeeze remain speculative.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

The FDAs acceptance of Intellias lonvo-z application for priority review has focused attention on its potential to bring a one-time gene-editing treatment for hereditary angioedema toward commercialization. Bulls see the regulatory milestone and Phase 3 results as validation, while skeptics point to financing and launch risks and question why the shares have reacted modestly.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

T-Mobile is drawing attention after SpaceXs spectrum deal intensified fears that Starlink Mobile could eventually compete with established wireless carriers, contributing to a sharp telecom selloff. Traders disagree on whether the threat warrants repricing now or is being overblown given the time, spectrum and ground infrastructure needed to build a rival network.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

SpaceXs planned acquisition of low-band spectrum for Starlink Mobile has fueled a sharp selloff in Verizon shares amid concerns about future competition from a satellite-terrestrial wireless network. Traders are split between viewing the move as a serious long-term threat to Verizons customer base and seeing the selloff as an overreaction given the years and infrastructure needed to build a competitive network; some are also drawn to Verizons dividend and lower share price.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

Long-term Treasury yields near multi-decade highs, amid inflation concerns tied partly to oil and expectations of a restrictive Fed, are weighing on TLT. Traders are split between expecting more downside as yields stay elevated and betting on a rebound or short squeeze after auction-related relief in yields.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

LINKs volatile rebound and repeated tests of resistance have fueled breakout talk, with bulls accumulating on dips while bears warn the move could fade. Traders also debate whether Chainlinks institutional and tokenization adoption will translate into lasting value for the LINK token.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias planned early exit from its Rockville headquarters and procedural extensions in its generic-patent litigation have fueled speculation that a sale or further settlements may be approaching, though neither is confirmed. Traders welcomed the share-price rebound but debated whether it reflects company-specific developments or broader biotech-sector strength, with some expecting the gains to fade.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T is under pressure after SpaceX agreed to acquire low-band spectrum for Starlink Mobile, heightening fears of long-term competition with established wireless carriers. Traders are divided between viewing the selloff as an overreaction given the time and infrastructure needed to build a rival network and seeing a meaningful future threat; many dip buyers point to AT&Ts dividend and existing business.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek 2026 Annual Meeting

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced it will present two presentations at the upcoming ObesityWeek 2026 Annual Meeting, taking place November 14-17, 2026, in Washington, D.C. The first late-breaking oral presentation will feature topline results from...

Amylyx Pharma Q2 2026 Earnings Call Transcript

Amylyx Pharma (NASDAQ:AMLX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call.
This transcript is brought to you by Benzinga APIs. For real-time access to ourread more...

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that management will present at the Stifel 2026 Virtual Cardiometabolic Forum. The fireside chat will take place on Wednesday, September 30th, 2026, at 9:30 a.m. ET. A live webcast of the presentation can be...

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that management will present at the 24th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will take place on Tuesday, September 15th, 2026, at 12:20 p.m. ET. A live webcast of the presentation...

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

Key PointsAnalysts also raised their price targets on the company...

Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? 

Equity

Strong results, clinical progress, capital raises and bullish analyst calls boosted investor confidence. 


Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to...

AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win

Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.

Dow, S&P 500, Nasdaq Futures Slip As Global Bond Rout Catches Up With Markets: LUNR, MSTR, WYFI, AMLX Stocks In Focus

The U.S. 30-year Treasury yield climbed to a fresh 19-year high on Tuesday, trading at 5.274% at the time of writing, while the 10-year Treasury yield was at 4.692%.

Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today? 

Investors responded to clinical progress, improving commercial performance and new growth opportunities.


Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

AMLX News